Mineralys Therapeutics, Inc. (MLYS) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Radnor, PA, United States. The current CEO is Jon Congleton.
MLYS has IPO date of 2023-02-10, 51 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $1.81B.
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
